Ionis Pharmaceuticals (IONS) Convertible Debt (2009 - 2026)

Ionis Pharmaceuticals' Convertible Debt history runs 18 years deep, the most recent figure standing at $568.5 million for Q1 2026.

• On a quarterly basis, Convertible Debt changed 0.5% year-over-year to $568.5 million in Q1 2026; TTM through Mar 2026 was $568.5 million, a 0.5% change from a year earlier, with the FY2025 full-year figure at $751.5 million, up 33.0% from the prior year.
• Convertible Debt eased to $568.5 million in Q1 2026 per IONS's latest filing, from $751.5 million in the prior quarter.
• Across five years, Convertible Debt topped out at $751.5 million in Q4 2025 and bottomed at $114.1 million in Q2 2023.
• The 5-year median for Convertible Debt is $567.8 million (2025), against an average of $568.0 million.
• Across the five-year window, Convertible Debt plunged 79.01% in 2023 and soared 449.57% in 2024, its largest moves.
• Year by year, Convertible Debt stood at $544.5 million in 2022, then gained by 14.85% to $625.4 million in 2023, then declined by 9.65% to $565.0 million in 2024, then soared by 33.0% to $751.5 million in 2025, then slipped by 24.35% to $568.5 million in 2026.
• Per Business Quant, the three latest IONS Convertible Debt figures stand at $568.5 million (Q1 2026), $751.5 million (Q4 2025), and $567.1 million (Q3 2025).